Research programme: anti-infectives - NanoBio

Drug Profile

Research programme: anti-infectives - NanoBio

Alternative Names: NB-005; NB-201; NB-401; NB-402; Topical nanoemulsions for bacterial infections - NanoBio; Vaginitis nanoemulsion (NB Prototype-1); Vaginitis nanoemulsion (NB Prototype-2)

Latest Information Update: 19 Sep 2012

Price : $50

At a glance

  • Originator NanoBio Corporation
  • Developer NanoBio Corporation; University of Michigan Medical School
  • Class
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Burn infections; Cystic fibrosis-associated respiratory tract infections; Herpes simplex virus infections; Influenza virus infections; Methicillin-resistant Staphylococcus aureus infections; Vaginitis; Wound infections
  • Discontinued Herpes zoster

Most Recent Events

  • 19 Sep 2012 Discontinued - Preclinical for Herpes zoster in USA (Topical) before 2012
  • 12 Sep 2012 NB 401 is still in active development for Cystic fibrosis-associated respiratory tract infections, including MRSA based on information presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012) ,
  • 12 Sep 2012 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top